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Abstract
Health related quality of life (HRQOL) can better re-
flect changes in acquired immune deficiency syn-
drome (AIDS) patients and inform economic evalua-
tion of AIDS treatment services, and the assess-
ment of HRQOL can help us to detect problems
that may influence the progression of the disease,
hence HRQOL has become a particularly important
assessment indictor for HIV comprehensive inter-
ventions. Being a multi-angle, multi-level, and di-
versified complex intervention, roles of Chinese
medicine (CM) in AIDS treatment have been recog-
nized and accepted by more and more patients,
and HRQOL has been widely used to evaluate the
comprehensive management effects of CM on
AIDS. In this article, the authors analyze the defini-
tion and measurement of HRQOL, measurement of
HRQOL of HIV/AIDS patients and effects of CM on
AIDS, and give some reasonable advices for the us-
age of the scale of HRQOL. The authors hold that
some new HRQOL instruments specific for CM treat-
ment of AIDS should be developed and further pro-
spective studies should be carried out to demon-
strate the practicality, reliability and validity of
HRQOL as an evaluation indictor for CM treatment
of AIDS.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Acquired immune deficiency syndrome (AIDS) is a
communicable disease recognized in the early 1980s,
which is caused by the human immunodeficiency virus
(HIV) infection. More than 35.0 million people were
living with HIV worldwide and millions of patients
died of the complex HIV related and non-related rea-
sons in the past 30 years. To date, this global tragedy
might continue to the foreseeable future because the
prospect of an effective HIV vaccine to contain the
pandemic remains uncertain1 and there is no cure
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method for this troublesome disease. Fortunately, with
the scale-up of combined antiretroviral therapy
(cART), early detection and treatment, and the preven-
tion of opportunistic infections, etc., HIV-related mor-
bidity and mortality have been reduced dramatically.2
AIDS has become a chronic disease with a lifelong
medication.
According to Western Medicine (WM) or convenient
medicine, AIDS is caused by HIV infection. If the in-
fection is not detected and treated, the immune system
gradually weakens and AIDS develops. Thus, how to
eliminate, diminish or suppress the level of plasma
HIV virus loads and to improve immune system are
the main goals for WM especially for cART in order to
restore and preserve immunological function, prevent
opportunistic diseases and reduce mortality. Now,
CD4+ T cell counts and plasma HIV virus loads are
recommended as a main and golden evaluation criteri-
on and are used in researches, clinical practice, and
drug screening. In addition, there are some other evalu-
ation indexes for AIDS treatment and control such as
health related quality of life (HRQOL), survival rate,
HIV infection rates, etc. Especially HRQOL has be-
come as a main concern on health for people living
with HIV (PLWH) and professionals in the recent
years.
In this article, after the definition and measurement of
HRQOL, measurement of HRQOL of HIV/AIDS pa-
tients and effects of CM on AIDS treatment are ana-
lyzed, merits and defects of HRQOL as an evaluation
indicator for CM treatment of AIDS are commented
and some reasonable advices are given for the usage of
the scale of HRQOL.
DEFINITION ANDMEASUREMENT
OF HEALTH RELATED QUALITY OF
LIFE
Since 1990s, with the transformation of medical mod-
el, the definition of health has changed. Health is not
only absence of disease or illness, but also the physical,
psychological state and social environment maintain in
a good condition. The shift of the concept promotes
values of social psychological factors, life style and be-
havior on the health. Disease and clinical efficacy are
not simply evaluated with only objective measures of
disease, but a comprehensive concept of psychological,
physiological and social functions, especially for chron-
ic disease. Here, the quality of life (QOL) was intro-
duced.
According to World Health Organization (WHO),
QOL is defined as "an individual's perception of the
position in life in the culture and value systems in
which they live, and in relation to their goals, expecta-
tions, standards and concerns",3 being a multidimen-
sional concept of the physical, psychological and social
function status. QOL is a subjective health evaluation
index and it is closely related with the specific back-
ground of culture and social circumstance.
At present, QOL is an aspect throughout the long ther-
apeutic process of some chronic diseases. Being a sub-
jective evaluation indicator, HRQOL has been widely
used in many chronic diseases including cancer, stroke,
coronary heart disease and diabetes. HRQOL focuses
on QOL specifically, as it is the main concern of health
care for professionals.4 The HRQOL also is an impor-
tant indictor to detect changes in functional status over-
time, evaluate intervention effects, and improve pa-
tient-provider communication and adhere to medica-
tions.5
In order to assess HRQOL of patients, numerous tools
have been developed. HRQOL can be measured
through the two basic approaches: generic instruments,
e.g. Karnofsky Performance Scale Index (KPSI) ,6 Medi-
cal Outcome Study 36-item short-form (SF-36),7 Not-
tingham Health Profile (NHP) 8 and Quality of Life In-
dex (QL-Index),9 etc.; and disease specific instruments,
e.g. Minnesota Living with Heart Failure Question-
naire (MLHFQ)10 and Diabetes Specific Quality of
Life Scale (DSQL),11 etc., which are not mutually exclu-
sive. Each approach has its advantages and weaknesses,
and may be suitable for different circumstances.12
Currently, the generic and disease specific instruments
are often used for any studies at the same time, so the
instrument of HRQOL should be used appropriately
and the user must follow the manual to measure
HRQOL.
Briefly, to update, being a multidimensional concept,
HRQOL has been commonly recognized as an impor-
tant concern in patient care. A lot of tools have been
developed to measure HRQOL, and researchers have
used them as an important indictor in their researches
and clinical practices.
HRQOLMEASUREMENT OF HIV/
AIDS PATIENTS
HRQOL has become a particularly important assess-
ment for HIV infection is a chronic and no cure dis-
ease but with the prospect of long-term survival.
HRQOL can better reflect changes in HIV/AIDS pa-
tients and inform economic evaluation of HIV/AIDS
treatment services,13 and the assessment of HRQL can
help us to detect the problems influencing the progres-
sion of the disease. The instruments of HRQOL for
HIV/AIDS patients and HIV related disease or symp-
tom are developed, including Patient Reported Out-
comes Quality of Life-HIV questionnaire (PRO-
QOL-HIV Questionnaire),14 World Health Organiza-
tion Quality of Life Questionnaire for HIV/AIDS
(WHOQOL-HIV),15 and HIV-related Fatigue Scale
(HRFS),16 etc.
It is well known that HRQOL of PLWH is significant-
ly lower than the general population, and can be affect-
ed by many factors such as physical and clinical charac-
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teristics of HIV/AIDS patients, e.g. sex,17 age,18 educa-
tion level,19 complication,20 immune status and viral
load,21 etc., and some non-medical factors , e.g. psycho-
logical,22 interpersonal,23 environment,24 etc. The
HRQOL related factors are so complex that some of
them are the protective factors, some are risk factors,
and some have a dual effect on the level of the patient's
HRQOL, i.e. cART can improve the HRQOL of pa-
tients, 25 but the pill burden and side effects of anti-ret-
roviral drugs would offset the beneficial effect26, and
even there are opposite results in different studies.
In China, HRQOL of PLWH is a major concern. The
assessment of HRQOL on HIV/AIDS patients has
been performed. Some instruments have been intro-
duced and/or applied in clinical trials and clinical prac-
tice, including WHOQOL-HIV-BREF, MOS-HIV
(Chinese version), 27 Dermatology Life Quality Index
(DLQI), 28 etc., and some new scales are in develop-
ment , e.g. HIV/AIDS Quality of Life Questionnaire
(HIV/AIDSQOL-46), 29 etc.
EFFECTS OF CHINESEMEDICINE ON
AIDSTREATMENT
In China, CM has a long history and a wide mass base
with a profound cultural background. AIDS has been
treated with CM in the last 30 years under the guid-
ance of CM theory.30 Some clinical research results
show the positive roles of CM in AIDS treatment.31,32 It
is reported that CM can reduce plasma HIV viral loads,33
promote immunity reconstitution,34 ameliorate symp-
toms and signs,35 improve the HRQOL,36 counteract
against the effects of anti-retroviral drugs,37 even is of
benefit to long-term survival of AIDS patients,38 etc.
Therefore, CM belongs to multi-angle, multi-level,
and diversified complex intervention.
Besides the advances of CM treatment of AIDS, some
Chinese herbs are screened for potential anti-HIV
drugs and some active ingredients extracted from com-
mon Chinese herbs are proved to have function of an-
ti-HIV replication in the laboratory, but very few herb-
al medicines show positive results for AIDS treatment
so that they can not be commercially exploited.39 More-
over, the negative role of some herbal medicines in
AIDS treatment is found.40 It is suggested that the effi-
cacy, safety and mechanism of herbal medicines in
AIDS treatment should be researched deeply. In short,
results of some clinical observations and researches
show positive action of CM on AIDS treatment, and
we should provide enough evidences for supporting
those effects and exploring the mechanism of CM in
laboratory perfectly.
HRQOL OF AIDS AND CHINESE
MEDICINE
There are more differences between CM and Western
Medicine (WM) in explaining disease or health.41 Ac-
cording to CM theory, the patient has abnormal symp-
toms, signs, pulse or tongue picture caused by basic
pathological factors , i.e. an abnormal status and ／ or
outcomes of "Yin-Yang", "Qi-blood", " cold-heat" or
"deficiency-excess". CM more emphasizes integrative
systemic treatment and individual treatment for the pa-
tient. When CMPs give treatments to their patients, of-
ten focus on adjusting the balance of "Yin" and
"Yang", and harmonizing relations between internal
pathophysiological function and external natural envi-
ronment changes of the patient through CM meth-
ods , e.g. strengthening body resistance and eliminat-
ing evil,42 replenishing Qi and detoxification,43 etc.,
combined with some humanistic concerns, e.g. assist-
ing patient to regulate abnormal emotion, giving some
advices for the abnormal changes of daily life mode, of-
fering some general medical knowledge on disease pre-
vention and control, etc.
For the intrinsic difference of CM and WM, assess-
ment of CM is also different with WM. For CMPs, the
efficacy evaluation is related to not only the pathologi-
cal and physiological improvement such as laboratory
or physical examinations developed from WM, but al-
so the perception of the patient on the complexion,
spirit, vitality and social function changes which can-
not be measured by laboratory or physical examina-
tions. Thus, based on the holistic view, CM combined
with syndrome differentiation and humanistic care is
likely to have positive impacts on patients' physiologi-
cal function, psychological function, independence, so-
cial relationship, personal faith and ／or environment
relationships; and all these positive improvements are
related to the better HRQOL of patients.
In the last 30 years, CM treatment has been considered
to possess the advantage of improving HRQOL of pa-
tients of some chronic diseases, and some evidences al-
so demonstrated the improvement of the HRQOL of
the patients with cancer, coronary disease or mental ill-
nesses after the complex CM interventions. For exam-
ple, a prospective and longitudinal study in Hong
Kong shows that CM is associated with significant im-
provement of HRQOL of patients and can be used as
an alternative primary care service.44 A systematic re-
view shows that it is possible that oral Chinese herbal
medicine used in conjunction with chemotherapy may
improve QOL in non-small cell lung cancer.45 Further-
more, it should be pointed out that no enough evi-
dence may prove the advantage of improving HRQOL
of patients by CM intervention, and studies with bet-
ter designs and longer duration should be carried out
to ascertain the actual impact of CM on patients'
HRQOL with a specific HRQOL instrument for CM,46
etc. In brief, CM treatment can be used to improve
HRQOL of patients and the assessment of HRQOL
has also been used as an important outcome indicator
to evaluate the CM intervention.
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As a key evaluation index, HRQOL has also been used
to evaluate the efficacy of the intervention on AIDS
treatment, not limited to cART. Although the related
researches are not many, some researchers have used
HRQOL to evaluate the efficacy of CM on AIDS treat-
ment. For example, a recent study on quality of life of
the asymptomatic HIV infected person treated with
CM shows that syndrome differentiation treatment
can significantly improve the patient's QOL;47 and in
another one-year study using Chinese herbal medicine
(CHM), researchers also find that the total score of
WHO-HIV is improved after one-year therapy in 43
cases of PLWH.48 But in a prospective, placebo-con-
trolled double-blind study, the standardized formula-
tion of Chinese herbs for HIV infected individuals
does not improve quality of life, clinical manifesta-
tions, plasma HIV virus loads, or CD4+T cell counts.49
Therefore, there still is absent of enough systematic
study on HRQOL of PLWH treated with CM.
Shortly, HRQOL has been used to evaluate the effect
of CM on AIDS treatment, and it seems a good evalua-
tion index for AIDS treatment with CM, but with few
enough evidence to support. CMPs should carry out
some well designed and controlled researches to dem-
onstrate whether HRQOL is an appropriate evaluation
index for CM treatment of AIDS in the future.
DEFECTS OF EXISTING HRQOL
INSTRUMENTSTO EVALUATE CM
Despite HRQOL has been used to evaluate the effect
of CM on AIDS by the existing scales introduced from
WM, their validity needs to be confirmed because of
the distinctive difference between Western culture and
Chinese culture. Especially, the evaluation of CM
should be based on its philosophy and theory so as to
be sensitive and responsive to the changes brought
about by CM.
Therefore, we should not abandon few enough evidenc-
es to support the improvement of HRQOL by CM in-
tervention. It still remains uncertain whether the re-
sults truly reflect those related to CM, and some new
HRQOL instruments specific for AIDS CM treatment
should be developed.
CONCLUSION
HRQOL can better reflect changes in HIV/AIDS pa-
tients and inform economic evaluation of HIV/AIDS
treatment services, and the assessment of HRQL can
help us to detect the problems that may influence the
progression of the disease.
To date, HRQOL has become a particularly important
assessment for HIV comprehensive interventions. Be-
ing a multi-angle, multi-level, and diversified complex
intervention, the roles of CM in AIDS treatment have
been recognized and accepted by more and more pa-
tients, and HRQOL has been widely used to evaluate
those comprehensive management effects of CM on
AIDS.
But some new HRQOL instruments specific for CM
in AIDS treatment should be developed, and the fur-
ther prospective studies should be carried out to dem-
onstrate the practicality, reliability and validity of
HRQOL as an evaluation index for CM treatment of
AIDS.
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